Fig. 2

Changes in clinical effectiveness at every 3 months after initiation of dulaglutide or liraglutide (based on the propensity-score-matched sample). a HbA1c values from baseline to month 12, b change in HbA1c from baseline to month 12, c body weights from baseline to month 12, d change in body weight from baseline to month 12, e systolic blood pressure (SBP) from baseline to month 12, f change in SBP from baseline to month 12, g alanine aminotransferase (ALT) values from baseline to month 12, h change in ALT from baseline, i estimated glomerular filtration rates (eGFR) from baseline to month 12, and j change in eGFR from baseline to month 12. Index date refers to the first date of initiation of dulaglutide or liraglutide. *, **, and *** refer to p value < 0.05, < 0.01, and < 0.001, respectively